We are live on ! Find out more
DAWN

Day One Biopharmaceuticals
DAWN

Delisted

DAWN was delisted on the 22nd of April, 2026.

Back to rankings

140 hedge funds and large institutions have $941M invested in Day One Biopharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 60 increasing their positions, 23 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

161% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 23

56% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 25

33% more call options, than puts

Call options by funds: $1.74M | Put options by funds: $1.31M

23.94% more ownership

Funds ownership: 83.18% → 107.12% (+24%)

15% more capital invested

Capital invested by funds: $818M → $941M (+$123M)

11% more funds holding

Funds holding: 126 → 140 (+14)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
140
Holders Change
+14
Holders Change %
+11.11%
% of All Funds
2.2%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
39
Increased
60
Reduced
23
Closed
25
Calls
$1.74M
Puts
$1.31M
Net Calls
+$429K
Net Calls Change
-$526K

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$22.2M
2
BlackRock
BlackRock
New York
+$17.1M
3
DM
Deerfield Management
New York
+$16.6M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$15M
5
PHS
PFM Health Sciences
California
+$15M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$13.2M
2
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$5.38M
3
Renaissance Technologies
Renaissance Technologies
New York
-$3.13M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$2.76M
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$2.36M
Name Holding Trade Value Shares
Change 		Change in
Stake
LGM
26
Logos Global Management
California
$7.76M +$8.49M +650,000 New
SFM
27
Sphera Funds Management
Israel
$6.33M +$6.92M +530,000 New
Verition Fund Management
28
Verition Fund Management
Connecticut
$6.1M +$6.29M +481,935 +1,643%
DCM
29
DAFNA Capital Management
California
$6.05M +$6.62M +507,100 New
AG
30
Artal Group
Luxembourg
$5.97M +$6.53M +500,000 New
Millennium Management
31
Millennium Management
New York
$5.83M +$3.51M +268,454 +122%
DCM
32
Driehaus Capital Management
Illinois
$5.71M +$81.3K +6,222 +1%
Northern Trust
33
Northern Trust
Illinois
$5.17M +$2.78M +213,071 +97%
PHP
34
Parkman Healthcare Partners
Connecticut
$5.11M +$366K +28,059 +7%
Alyeska Investment Group
35
Alyeska Investment Group
Illinois
$4.66M +$1.63M +125,000 +47%
N
36
Nuveen
North Carolina
$4.21M -$1.91M -146,025 -29%
Charles Schwab
37
Charles Schwab
California
$3.85M +$1.56M +119,421 +59%
Rafferty Asset Management
38
Rafferty Asset Management
New York
$3.47M +$1.3M +99,563 +52%
CS
39
Candriam SCA
Luxembourg
$3.46M +$1.3M +99,821 +52%
Morgan Stanley
40
Morgan Stanley
New York
$2.84M +$702K +53,785 +29%
Bank of America
41
Bank of America
North Carolina
$2.55M -$263K -20,118 -9%
D.E. Shaw & Co
42
D.E. Shaw & Co
New York
$2.55M -$2.76M -210,963 -50%
WP
43
Woodline Partners
California
$2.52M +$783K +59,972 +40%
MIM
44
Monashee Investment Management
Massachusetts
$2.39M +$2.61M +199,900 New
SB
45
Samsara BioCapital
California
$2.35M – – –
ECM
46
ExodusPoint Capital Management
New York
$2.23M +$2.44M +187,185 New
Dimensional Fund Advisors
47
Dimensional Fund Advisors
Texas
$2.19M -$2.36M -180,881 -50%
Bank of New York Mellon
48
Bank of New York Mellon
New York
$2.15M +$892K +68,278 +61%
Norges Bank
49
Norges Bank
Norway
$2.02M – – –
Deutsche Bank
50
Deutsche Bank
Germany
$2M -$5.45K -417 -0.2%
1
2
3 4 5

DAWN Hedge Fund Activity: Q2 2023 in Review

140 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Day One Biopharmaceuticals (DAWN) for Q2 2023, worth a combined $941M — up 15% from $818M a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new DAWN positions and 25 closed out — a net gain of 14 holders — while 60 added to existing stakes and 23 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $22.2M. The largest seller was Fidelity Investments, cutting an estimated $13.2M.

  • 140 institutional investors held Day One Biopharmaceuticals (DAWN) as of Q2 2023, up from 126 in Q1 2023.
  • Funds reported $941M of Day One Biopharmaceuticals stock for Q2 2023, up 15% quarter-over-quarter.
  • 39 funds opened new Day One Biopharmaceuticals positions in Q2 2023 and 25 closed out, a net change of +14 holders.
  • The largest Day One Biopharmaceuticals buyer in Q2 2023 was Adage Capital Partners, an estimated $22.2M added.
  • The largest Day One Biopharmaceuticals seller in Q2 2023 was Fidelity Investments, an estimated $13.2M sold.

Based on aggregated 13F filings for Q2 2023.